Institution
Sichuan University
Education•Chengdu, China•
About: Sichuan University is a education organization based out in Chengdu, China. It is known for research contribution in the topics: Population & Catalysis. The organization has 107623 authors who have published 102844 publications receiving 1612131 citations. The organization is also known as: Sìchuān Dàxué.
Topics: Population, Catalysis, Cancer, Adsorption, Randomized controlled trial
Papers published on a yearly basis
Papers
More filters
TL;DR: In this article, the possibility to enhance polymer/filler interfacial interaction via crystallization of polymer on the surface of fillers, i.e., interfacial crystallization, is summarized and discussed in this paper.
317 citations
TL;DR: It is shown by fate mapping, clonal analysis, and immunohistochemistry that endocardial cells generate the endothelium of coronary arteries, indicating that the coronary arteries and veins have distinct origins and are formed by different mechanisms.
317 citations
TL;DR: This tutorial review will focus on chiral Lewis base-catalysed asymmetric transformations of MBH adducts, especially those developed over the past five years, allowing for the rapid construction of densely functionalised chiral molecules with high levels of regio- and stereoselectivities.
Abstract: Chiral Lewis basic tertiary amines or phosphines can enable properly modified Morita–Baylis–Hillman (MBH) adducts to undergo asymmetric allylic substitutions with a wide range of nucleophiles. In addition, assisted by a Bronsted base, chiral Lewis bases can also catalytically convert modified MBH adducts into allylic ylides, which can be engaged in a variety of asymmetric annulation reactions. This tutorial review will focus on such chiral Lewis base-catalysed asymmetric transformations of MBH adducts, especially those developed over the past five years, allowing for the rapid construction of densely functionalised chiral molecules with high levels of regio- and stereoselectivities.
316 citations
TL;DR: In this article, a series of crosslinked PLA materials with different gel fraction and crosslink density were characterized by FTIR, and the thermal and mechanical properties of samples were also investigated by means of differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), tensile testing and dynamic mechanical analysis (DMA).
316 citations
Medical University of Łódź1, Zhejiang University2, Peking Union Medical College3, Sichuan University4, Katholieke Universiteit Leuven5, Mahidol University6, Russian Academy7, University of São Paulo8, Medical University of Vienna9, Masaryk University10, Tokyo Metropolitan Komagome Hospital11, Janssen Pharmaceutica12, Johnson & Johnson Pharmaceutical Research and Development13
TL;DR: VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity.
Abstract: BackgroundThe proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma. MethodsIn this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). The primary end point was progression-free survival. ResultsAfter a median follow-up of 40 months, median progression-free survival (according to independent radiologic review) was 14.4 months in the R-C...
316 citations
Authors
Showing all 108474 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Jie Zhang | 178 | 4857 | 221720 |
| Robin M. Murray | 171 | 1539 | 116362 |
| Xiang Zhang | 154 | 1733 | 117576 |
| Rui Zhang | 151 | 2625 | 107917 |
| Xiaoyuan Chen | 149 | 994 | 89870 |
| Yi Yang | 143 | 2456 | 92268 |
| Xinliang Feng | 134 | 721 | 73033 |
| Chuan He | 130 | 584 | 66438 |
| Lei Zhang | 130 | 2312 | 86950 |
| Jian Zhou | 128 | 3007 | 91402 |
| Shaobin Wang | 126 | 872 | 52463 |
| Yi Xie | 126 | 745 | 62970 |
| Pak C. Sham | 124 | 866 | 100601 |
| Wei Chen | 122 | 1946 | 89460 |
| Bo Wang | 119 | 2905 | 84863 |